Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 4/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900463 | 0.93 | MEN1 (0.33) | MEN1KMT2ACCKBR | |
| SCHEMBL3902440 | 0.93 | CCKBR (0.38) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3905799 | 0.93 | CRHBP (0.38) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3907638 | 0.92 | KMT2A (0.34) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3913074 | 0.91 | MEN1 (0.32) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3908975 | 0.90 | KMT2A (0.38) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3900281 | 0.89 | KMT2A (0.38) | KMT2ACCKBR | |
| SCHEMBL3902433 | 0.88 | CRHBP (0.36) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3906317 | 0.87 | CCR2 (0.39) | MEN1KMT2ACCKBRCRHBPCRHR2 | |
| SCHEMBL3901168 | 0.87 | CRHBP (0.40) | MEN1KMT2ACCKBRCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1675837-A2 | BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005012275-A2 | BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | MEN1 2768/4885KMT2A 3053/4885CCKBR 1/4885 |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | CCKBR, CCKAR, BRSK2 | MEN1 2441/4885KMT2A 3281/4885CCKBR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.